ATLANTA, Oct. 30, 2014 /PRNewswire/ -- EndoChoice® announced the release of study data supporting the efficacy of the Fuse® Full Spectrum Endoscopy System®. These studies were presented simultaneously by leading gastroenterologists at the American College of Gastroenterology (ACG) Annual Scientific Session in Philadelphia, PA, and the United European Gastroenterology Week (UEGW) in Vienna, Austria.
Researchers at several international sites reported that seeing 94% more anatomy with the Fuse system has a statistically significant impact on the ability to detect precancerous lesions, efficiency in navigating the GI tract, and reductions in sedation requirements, when compared to traditional forward-viewing (TFV) endoscopes.1,2,3,4 Additionally, economic analyses projected the additional efficacy of Fuse would potentially result in the annual prevention of 10,318 new colorectal cancer diagnoses in the US and annual savings of $300,000,000 in colon cancer related costs to the US healthcare system.5
At UEGW, a team of researchers led by Dr. Helmut Neumann presented data from a recently completed prospective, parallel, randomized study comparing Fuse to TFV endoscopes. 57 patients were randomly assigned to undergo colonoscopy with Fuse or TFV. Performance characteristics including medication, patient and endoscopists' satisfaction, and polyp detection rates (PDR) were recorded. Satisfaction rates of patients and endoscopists were high throughout the cases and similar in both groups. However, patients in the TFV group required more sedation (mean propofol dosage: Fuse: 170 mg vs TFV: 230 mg). Although more polyps were found in the Fuse group (37% per patient PDR for Fuse vs 18% for TFV), the study was not powered to compare adenoma detection rates between groups.
"The mission of EndoChoice is to serve the GI caregiver through insight and innovation," said Mark Gilreath, Founder and CEO at EndoChoice. "The studies presented at UEGW and ACG this week provide further confirmation that Fuse enables physicians to provide a higher level of care for patients and further advance their practices."
Based in Atlanta GA, EndoChoice is a medtech company focused on the manufacturing and commercialization of platform technologies including devices, diagnostics, infection control and endoscopic imaging for specialists treating a wide range of gastrointestinal diseases. EndoChoice leverages its direct sales organization to serve more than 2,000 customers in the United States and works with 34 distribution partners world-wide. The Company was founded in 2008 and has rapidly developed a proprietary product portfolio, which includes the revolutionary Full Spectrum Endoscopy System (Fuse). 2014 marked the fifth consecutive year EndoChoice was recognized as one of the fastest growing companies in the U.S. by Inc. Magazine. To learn more, visit www.endochoice.com.
1 Neumann et al. Performance Characteristics of Colorectal Full Spectrum Endoscopy (Fuse) – Prospective, Parallel, Randomized Study. UEGW 2014.
2 Papanikolaou et al. Full Spectrum Endoscopy vs Traditional Forward-Viewing Colonoscopy with and without Right-Colon Retroflexion: A Randomized, Bicentric Back-to-Back Study. UEGW 2014.
3 Lewis et al. Increased Polyp Detection and Decreased Sedation Usage in an ASC Setting after Implementing Panorama Endoscopy Platform. ACG 2014.
4 Hassan & Gralnek. Fuse Colonoscopy Yields Higher Detection of Advanced and Multiple Adenomas As Compared to Standard Forward Viewing Colonoscopy: A Post-Hoc Per Patient Analysis from a Randomized Comparative Trial. UEGW 2014.
5 Hassan & Gralnek. The Cost-Effectiveness of "Full Spectrum Endoscopy (Fuse)" Colonoscopy for Colorectal Cancer Screening. UEGW 2014.
EndoChoice and Fuse are registered trademarks of EndoChoice, Inc.
For more information, press only:
Doug Ladd, Chief Marketing Officer
513-608-6873 or [email protected]
For more information on Fuse